Greenwich Lifesciences Inc Stock Price, News & Analysis

Greenwich LifeSciences (Nasdaq: GLSI) announced CEO Snehal Patel's participation in upcoming virtual investor conferences. The conferences will highlight GP2 trial data aimed at preventing breast cancer recurrences. Key events include: B. Riley Securities Oncology Investor Conference on January 21, 2021, and the BIO CEO & Investor Conference from February 16-18, 2021, featuring networking opportunities with investors. GP2 shows promising Phase IIb results, with no recurrences in 3+ HER2 patients after 5 years. Visit greenwichlifesciences.com for more details.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that its CEO, Snehal Patel, will participate in three virtual investor conferences during the week of January 11, 2021. These include the H.C. Wainwright BioConnect Conference with an on-demand presentation starting at 6:00 am EST, the Biotech Showcase 2021, and the BIO Partnering event at the 2021 JP Morgan Healthcare Conference. The company’s GP2 immunotherapy aims to prevent breast cancer recurrences in patients post-surgery, showing promising Phase IIb trial results with no recurrences in a specific patient group after five years.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that the replay of its December 15, 2020 presentation at the LD Micro Main Event is now available. CEO Snehal Patel highlighted the successful Phase IIb trial of GP2, which showed a remarkable 100% disease-free survival rate in HER2 positive patients over five years. The company plans to initiate a Phase III trial to further investigate GP2 as an immunotherapy for preventing breast cancer recurrences. For further details, the replay can be accessed through their website.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) will ring the Nasdaq opening bell on December 28, 2020, to celebrate its IPO completion. CEO Snehal Patel and the team will participate in a virtual ceremony starting at 9:20 am EST. The company has raised over $33 million to fund its GP2 immunotherapy aimed at preventing breast cancer recurrences. The Phase III clinical trial is set to commence, following positive results from a Phase IIb trial where no recurrences were observed in the HER2/neu 3+ adjuvant setting. This initiative aims to improve outcomes for breast cancer survivors.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has announced the closing of its underwritten public offering, yielding gross proceeds of $26.4 million. The funds will be allocated towards manufacturing and clinical trial completions for the GP2 Phase III trial, Biologics Licensing Application submission to the FDA, and development of additional products, including a coronavirus vaccine. An additional 99,000 shares may be purchased by underwriters to increase total proceeds to approximately $30.4 million.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced an upsized public offering, expected to raise approximately $26.4 million. The offering includes 660,000 shares priced at $40.00 per share, with a potential increase to $30.4 million if underwriters exercise their option for an additional 99,000 shares. Proceeds will fund clinical trials, completion of manufacturing, and support for a coronavirus vaccine program. The offering is set to close around December 22, 2020.

Greenwich LifeSciences (Nasdaq: GLSI) has announced an option agreement with Westport Bio to in-license a pre-clinical coronavirus vaccine program currently in animal testing. The agreement involves up to $250,000 in research sponsorship, plus additional fees. Westport Bio's vaccine candidates aim to enhance existing DNA/RNA vaccines. CEO Snehal Patel highlighted their aim to achieve greater protection against COVID-19, leveraging previous success with a pneumonic plague vaccine that provided 100% protection. The company remains focused on its GP2 breast cancer immunotherapy while exploring new candidates.

Greenwich LifeSciences announced the publication of a second poster for its GP2 Phase III clinical trial targeting breast cancer recurrence at the San Antonio Breast Cancer Symposium. The trial seeks to replicate previous results showing no recurrences in HER2/neu 3+ patients after treatment with GP2 + GM-CSF. The Phase III trial will include interim analysis for FDA marketing approval and involve 11 injections over three years. CEO Snehal Patel expressed confidence in the collaboration with Baylor College of Medicine to achieve these goals.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) presented a poster on the final efficacy analysis of its GP2 Phase IIb clinical trial at the San Antonio Breast Cancer Symposium. The trial demonstrated a 0% recurrence rate in HER2/neu 3+ patients after 5 years, validating GP2's potential as a treatment. CEO Snehal Patel indicated plans for a Phase III trial, addressing a significant unmet need in breast cancer treatment, with a potential market exceeding $5 billion. The study included 168 patients and indicated that GP2 could also be effective for HER2/neu 1-2+ populations.